Lilly (Eli) Cash Flow Statement
LLY / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Lilly (Eli) generated $16.8B in operating cash flow in FY2025. The company returned $5.4B in dividends and $4.1B in share buybacks to shareholders in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.02 (distress zone, below 1.8 threshold)
- Strong profit margin: 31.0%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 77.4%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $20.6B | $10.6B | $5.6B | $6.2B | $8.3B | $3.2B | $8.3B | $3.2B | $2.4B | $2.7B | $2.4B | $2.4B | $4.7B | $5.1B | $4.3B |
| Depreciation & Amortization | $2.0B | $1.8B | $1.5B | $1.3B | $1.2B | $1.6B | $1.2B | $1.6B | $1.4B | $1.5B | $1.4B | $1.4B | $1.4B | $1.3B | $1.3B |
| Operating Cash Flow | $16.8B | $8.8B | $7.4B | $6.5B | $4.8B | $5.5B | $4.8B | $5.5B | $3.0B | $4.9B | $3.0B | $4.5B | $5.7B | $6.9B | $4.3B |
| Share Buybacks | $4.1B | $2.5B | $1.3B | $500.0M | $4.4B | $4.2B | $4.4B | $4.2B | $749.5M | $600.1M | $749.5M | $800.0M | $1.7B | $0 | - |
| Dividends Paid | $5.4B | $4.7B | $3.1B | $2.7B | $2.4B | $2.3B | $2.4B | $2.3B | $2.1B | $2.2B | $2.1B | $2.1B | $2.1B | $2.2B | $2.2B |